AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn
23 Feb 2024
Cell TherapyImmunotherapyAcquisitionClinical StudyGene Therapy
Preview
Source: Pharmaceutical Technology
AstraZeneca will gain access to GC012F, a key asset from Gracell. Credit: rarrarorro / Shutterstock.com.
Preview
Source: Pharmaceutical Technology
AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn.
The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.
AstraZeneca will acquire all of Gracell’s fully diluted share capital, including that represented by American depositary shares, through a merger for $2 per ordinary share in cash.
This is in addition to a non-tradable contingent value right of $0.3 per ordinary share payable upon achievement of a specified regulatory milestone.
The upfront cash portion of the consideration represents a transaction value of $1.0bn.
See Also:AZD-9829 by AstraZeneca for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Preview
Source: Pharmaceutical Technology
AZD-9829 by AstraZeneca for Myelodysplastic Syndrome: Likelihood of Approval
Preview
Source: Pharmaceutical Technology
Gracell’s integration into AstraZeneca’s operations is a strategic move to bolster the latter’s pipeline with cell therapies for cancer and autoimmune diseases.
AstraZeneca will gain access to GC012F, a key asset from Gracell.
Designed to drive deep and durable responses with an improved safety profile, therapy is being developed as a treatment for multiple myeloma and other haematologic malignancies and autoimmune diseases, including systemic lupus erythematosus.
Gracell commenced a Phase Ib/II clinical trial of GC012F to treat patients with relapsed or refractory multiple myeloma in the US.
This month, AstraZeneca announced a $300m investment in a new facility in Rockville, Maryland. This investment is a significant step in launching its cell therapy platforms in the US, advancing critical cancer trials and preparing for future commercial supply.
The new facility is expected to create 150 skilled jobs, primarily focusing on the production of T-cell therapies to support clinical trials worldwide.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline
The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.